<DOC>
	<DOCNO>NCT01088880</DOCNO>
	<brief_summary>Establish safety efficacy 3 month treatment canakinumab patient colchicine resistant Familial Mediterranean Fever .</brief_summary>
	<brief_title>Efficacy Safety Canakinumab Patients With Colchicine Resistant Familial Mediterranean Fever</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Brucellosis</mesh_term>
	<mesh_term>Familial Mediterranean Fever</mesh_term>
	<mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female patient 12 75 year age active type 1 FMF disease ( accord TelHashomer criterion diagnosis FMF ) despite colchicine therapy ( 1.5 2.0 mg/day ) . Patients intolerant effective dos colchicine ( 1.5 2 mg/day ) Patients demonstrate minimum 1 typical acute attack per month genetic confirmation diagnosis ( least one know MEFV gene exon 10 mutation ) . Patients manifest amyloidosis exclude . Patients must historical data show frequency least 1 attack/month within last 3 month enter runin period . Patients must type 1 disease characterize recurrent short episode inflammation serositis average least 1 documented acute FMF attack per month previous 6 month last approximately 12 72 hour . Patients treat IL1 therapy must complete washout experience least 2 attack since ( e.g . Anakinra : 3 day washout ; Rilonacept : 3 week washout ) Patients treat antiTNF drug must undergo appropriate washout . Prior randomization , use Etanercept must discontinue 4 week use Adalimumab Infliximab must discontinue 8 week . Female subject childbearing potential must use two acceptable method contraception Patients treat Interferon therapy must complete 1 month washout period . Patients endorgan dysfunction due amyloidosis ( e.g . exist biopsy proven amyloidosis proteinuria &gt; 0.5 gram per day ) Patients take steroid within 1 month prior baseline Presence history inflammatory rheumatic disease Positive PPD test ( accord local guidance ) latent active TB infection exclude via Quantiferon ( TSpot radiographic image need ) . Patients pregnant lactate Presence active chronic infection major episode infection require hospitalization treatment i.v . antibiotic within 30 day oral antibiotic within 14 day prior screen History malignancy within last 5 year , except successfully excise squamous basal cell carcinoma skin Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Familial Mediterranean Fever</keyword>
	<keyword>canakinumab</keyword>
	<keyword>colchicine resistance</keyword>
</DOC>